Hari A. Deshpande, MD

Articles by Hari A. Deshpande, MD

The Use of Serum hCG as a Marker of Tumor Progression and of the Response of Metastatic Urothelial Cancer to Systemic Chemotherapy

ByKaren Malkhasyan, MD,Hari A. Deshpande, MD,Adebowale J. Adeniran, MD,John W. Colberg, MD,Daniel P. Petrylak, MD

October 15th 2013

A 55-year-old woman with a history of metastatic melanoma in remission for 8 years presented to the emergency department with gross hematuria. A CT scan, ordered because the patient was in menopause, demonstrated a bladder tumor.

Latest Updated Articles

The Use of Serum hCG as a Marker of Tumor Progression and of the Response of Metastatic Urothelial Cancer to Systemic Chemotherapy
Published: October 15th 2013 | Updated:

Hari A. Deshpande, MD

Articles by Hari A. Deshpande, MD

The Use of Serum hCG as a Marker of Tumor Progression and of the Response of Metastatic Urothelial Cancer to Systemic Chemotherapy

Latest Updated Articles

Trending on CancerNetwork

Casdatifan Monotherapy Achieves Clinical Activity in Late-Line Kidney Cancer

Antiemetic Regimen Limits Chemo-Induced Nausea/Vomiting in Multiple Myeloma

The Essential Role of Clinical Social Work in Oncology

Intravesical Mitomycin Produces Enduring Efficacy Across NMIBC Trials

How Will RLTs Be Integrated Into the Prostate Cancer Treatment Paradigm?